

# Ministry of Health

## Health Programs and Delivery Division

### Drug Submission Status

Report for December 2022

## Complete Streamlined Multiple-Source

### Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Glenmark Pharmaceuticals Canada Inc.	GLN-Apremilast	Otezla	APREMILAST	30 mg	tablet	02518910
Pharmascience Inc.	Pms-Apremilast	Otezla	APREMILAST	30 mg	tablet	02521733
Nora Pharma	NRA-Rizatriptan ODT	Maxalt	RIZATRIPTAN	10 mg	orally disintegrating tablet	02489384
Nora Pharma	NRA-Zolmitriptan	Zomig	ZOLMITRIPTAN	2.5 mg	tablet	02489392
Jamp Pharma Corporation	Jamp Clonidine	Dixarit	CLONIDINE HCL	0.025 mg	tablet	02528207
Sanis Health Inc.	Modafinil	Alertec	MODAFINIL	100 mg	tablet	02530244
Sanis Health Inc.	Moxifloxacin	Vigamox	MOXIFLOXACIN	0.50%	ophthalmic solution	02529076

Sandoz Canada Inc.	Sandoz Apremilast	OTEZLA	APREMILAST	30 mg	tablet	02529084
Natco Pharma (Canada) Inc.	Nat-Montelukast	Singulair	MONTELUKAST SODIUM	5 mg	chewable tablet	02522128
Natco Pharma (Canada) Inc.	Nat-Montelukast	Singulair	MONTELUKAST SODIUM	10 mg	tablet	02522136